Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - BIOLIFE SOLUTIONS INCv440425_ex99-1.htm

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

May 18, 2016

Date of report (Date of earliest event reported)

 

 

 

BIOLIFE SOLUTIONS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware 001-36362 94-3076866
(State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.)

 

3303 Monte Villa Parkway, Bothell, WA 98021

(Address of principal executive offices, including zip code)

 

(425) 402-1400

(Registrant’s telephone number, including area code)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

   

 

 

Item 7.01   Regulation FD Disclosure.

 

On May 18, 2016, BioLife Solutions, Inc. issued the press release entitled “BioLife Solutions Appoints Jim Mathers as New Vice President of Sales.” The press release is attached hereto as Exhibit 99.1. The information contained in the press release attached hereto is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that Section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01   Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press release dated May 18, 2016

 

   

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 18, 2016 BIOLIFE SOLUTIONS, INC.  
     
     
  By:  /s/ Roderick de Greef  
    Roderick de Greef
Chief Financial Officer
 

 

   

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
99.1   Press release dated May 18, 2016